Refractory plasmablastic lymphoma—a review of treatment options beyond standard therapy
- 23 December 2016
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (6) , 967-970
Abstract
Plasmablastic lymphoma (PBL) is a rare distinct subtype of aggressive diffuse large B-cell lymphoma and a notoriously hard to treat entity with a dismal prognosis in both HIV-negative and HIV-positive patients. Clinicians often face the question of second or third line treatment. As the treatment options with novel agents in lymphomas are rapidly evolving, more and more options beyond standard chemotherapy are available. In connection with a review of treatment options with novel lymphoma agents, we present a case report of a patient with a complete remission after the administration of brentuximab vedotin and lenalidomide.Keywords
This publication has 14 references indexed in Scilit:
- Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphomaAnnals of Hematology, 2016
- Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patientsJournal of Hematology & Oncology, 2015
- The biology and treatment of plasmablastic lymphomaBlood, 2015
- Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphomaLeukemia & Lymphoma, 2015
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell LymphomaNew England Journal of Medicine, 2015
- Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: A ReviewTransplantation and Cellular Therapy, 2014
- CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMAMediterranean Journal of Hematology and Infectious Diseases, 2014
- Brentuximab Vedotin Demonstrates Activity in a Patient With Plasmablastic Lymphoma Arising From a Background of Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2013
- Patient With HIV-Associated Plasmablastic Lymphoma Responding to Bortezomib Alone and in Combination With Dexamethasone, Gemcitabine, Oxaliplatin, Cytarabine, and Pegfilgrastim Chemotherapy and Lenalidomide AloneJournal of Clinical Oncology, 2010
- Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profilesLaboratory Investigation, 2005